An ageing population, rising antimicrobial resistance, and the ongoing threat of infectious and chronic diseases are placing immense pressure on our societies. A shift to a preventative approach is necessary for the efficiency and sustainability of our healthcare systems. Central to this shift is the often-underutilized tool of life-course immunization.
Open Access Government looks into the National Institute of General Medical Sciences (NIGMS)’s Biochemistry and Bio-related Chemistry Branch, and its current research areas and priorities.
Those newly diagnosed with Type 2 diabetes and heart failure are at the greatest 5-year risk of death, according to scientists at The American Heart Association.
In the last six months GreenLight Medicines has successfully out-licenced leads from its research, branching out internationally and attracting major investors.
Neil Osheroff from the Vanderbilt University School of Medicine is working to overcome drug resistance and revitalise the use of established targets for antibacterial agents, as we discover here.
Here, Megan Warrender looks into the strides being made by the NIDCR to support dental research and innovation, and, in particular, how current initiatives feed into long term plans for dental, oral and craniofacial health and disease in the U.S.
Prof Monica Di Luca, President, European Brain Council, highlights the importance of continuous prioritisation and attention to brain research during the COVID-19 pandemic.
Dr. Josef Penninger led an international team from the University of British Columbia to pioneer a trial drug that could stop infection in the early stages of COVID-19.
